 |
Current SVLSF investmentsPlease see below a list of all our current investments by fund To go to individual portfolio companies websites please click on company logo. SV Life Sciences Fund I (SVLSFI)
Micromet: Germany
First investment: 1998 - Start Up Micromet designs and develops novel antibody derived therapeutics for the treatment of cancer diseases. These drugs are unique in their ability to engage immune effector cells to selectively eliminate disease causing cells. SV Life Sciences Fund II (SVLSFII)
Achillion: US
First investment: 2000 - Start Up Achillion is based in New Haven, CT, Achillion is focused on the discovery, development and commercialization of innovative small molecule therapeutics for the treatment and/or prevention of serious infections associated with drug resistant viruses or bacteria. 
AcuFocus: US
First investment: 2001 - Seed AcuFocus is based in Irvine, CA, AcuFocus is developing an implantable corneal in-lay for correction of presbyopia. 
AllianceCare: US
First investment: 2000 - Start Up AllianceCare is based in Boynton Beach, FL, a senior healthcare provider of nursing and physician housecall services, rehabilitation therapy and home health services through 20 branch offices and over 150 senior communities located in Florida, Texas and Ohio. The “At Home” merger also added private duty home care services in MA, IL, DC, MD, GA, and PA. 
Cadent Technologies: US
First investment: 2000 - Early Stage Cadent is based in Carlstadt, NJ and has developed proprietary computer aided design (CAD/CAM) applications for the orthodontist and dental markets, which are deployed via a web-based service model on a pay per use basis. 
CardioFocus: US
First investment: 1999 - Early Stage CardioFocus is based in Marlborough, MA and has developed a catheter based approach using laser energy with visualization focused on atrial fibrillation. 
Cellzome: Germany
First investment: 2001 - Start Up Cellzome is a drug discovery company building a R&D pipeline in chronic diseases by leveraging its unique drug proteomics engine. The business is based in Heidelberg, Germany and Cambridge, UK. 
Cognis: Luxembourg
First investment: 2001 - Buyout Cognis is a global supplier of specialty chemicals using renewable, bio-degradable,natural oils as the key raw material base. Customers include international manufacturers of cosmetics, vitamins and nutritional supplements and homecare products as well as a broad range of industrial customers. 
Oxagen: UK
First investment: 2000 - Expansion Oxagen, based in Oxford, UK, is a biopharmaceutical company building a novel drug pipeline based on targets validated in man through its genetic platform. Oxagen’s work is focused in inflammatory and metabolic diseases. 
Quick Study Radiology: US
First investment: 2000 - Start Up QSR based in St. Louis, MO, sells comprehensive digital imaging services to community hospitals and imaging centers. The company integrates, manages and supports clinical and data systems for customers with a focus on underserved small and secondary city locations. SV Life Sciences Fund III (SVLSFIII)
Alba Therapeutics: US
First investment: 2005 - Early Stage Alba is based in Baltimore, MD, is focused on the development and commercialization of pharmaceuticals for the treatment of inflammatory and immune mediated diseases. Alba’s technology provides the ability to transiently open or close internal barriers such as the intestinal mucosa. Alba is applying its technology to develop treatments for celiac disease and other autoimmune conditions. 
Alinea: US
First investment: 2005 - Expansion 
AqueSys: US
First investment: 2006 - Early Stage AqueSys is based in Duluth, GA; AqueSys (TIF company) is developing an innovative approach to reducing intra-ocular pressure to treat glaucoma. 
Archemix: US
First investment: 2002 - Early Stage Archemix is based in Cambridge, MA, developing nucleic acid aptamers for therapeutic indications, building on a broad IP portfolio acquired from Gilead/Nexstar. 
CHF Solutions: US
First investment: 2005 - Expansion CHF is based in Brooklyn Park, MN and has developed a mechanical pump/filter system to remove excess fluid from patients with acute de-compensated congestive heart failure. The product has US 510k clearance and is CE marked for both in-patient hospital care and out-patient clinic use. 
Concentric Medical: US
First investment: 2003 - Expansion Concentric is based in Mountain View, CA. Designing and developing products to open the pathway for stroke treatment. Their first device, the MERCI Retriever, removes clots associated with ischemic strokes. 
CoreLab Partners: US
First investment: 2004 - Expansion CoreLab Partners based in Rockville, MD, provides ECG core lab services related to cardiac safety testing for global clinical trials. Formerly known as Medifacts International. 
Delenex Therapeutics: Switzerland
First investment SVLSF III: 2009 - Early Stage Delenex is a spin out from ESBATech, an investment that was divested in 2009. The business focuses on research and development in to its antibody fragments for delivering next generation Therapeutics application. 
EBR Systems: US
First investment: 2005 - Early Stage EBR Systems is developing a wireless cardiac stimulation device (WiCS) to compete in the cardiac resynchronization therapy space for treatment of congestive heart failure. 
Entellus: US
First investment: 2006 - Early Stage Entellus is a company developing medical device therapies for nasal and sinus disease. 
ESBATech: Switzerland
First investment: 2006 - Early Stage ESBATech is a preclinical stage drug discovery company that intends to refocus the business to build a world class Ophthalmology company on the back of an attractive, proprietary antibody fragment platform which can deliver uniquely stable, soluble and monomeric fragments and compelling data on penetration of these fragments into the eye following topical treatment. 
Ikano: US
First investment: 2006 - Early Stage Intranasal Therapeutics, Inc. (“ITI”) based in Montvale, NJ, is a specialty pharmaceutical company focused on developing innovative, nasally delivered pharmaceutical products with a particular focus on drugs treating pain and CNS-related disorders for which there is proven, unsatisfied consumer demand. The company will be developing new formulations of already marketed drugs and will pursue U.S. regulatory approval using the FDA 505(b)2* regulations. Formerly known as Intranasal Therapeutics. 
Lux Biosciences: US
First investment: 2006 - Seed Lux is developing drugs for ophthalmic diseases. Their lead products are a Cyclosporin implant for corneal transplant,and ISA247 for uveitis. Both programs are in Phase III development. Additional programs are an ISA247 implant for dry eye and Age-related Macular Degeneration. 
Mpex Pharmaceuticals: US
First investment: 2005 - Early Stage Mpex based in San Diego, CA, is focused on the discovery and development of new-antibacterial drugs that meet the growing clinical need created by multi-drug resistant bacteria. Mpex has identified several approaches to increase the effectiveness of existing antibiotics and decrease the incidence of drug resistance to these antibiotics. Mpex’s first product will be an inhaled antibiotic for serious lung infections. 
NeoVista: US
First investment: 2003 - Seed NeoVista based in Fremont, CA, is developing a surgical device for controlled irradiation to target tissue for arresting the progression of neovascularization, the cause of Wet AMD. 
Neurotech: US
First investment: 2006 - Early Stage Neurotech based in Lincoln, RI, has developed an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases. The first product is ciliary neurothrophic factor (CNTF) for retinitis pigmentosa and age-related macular degeneration (geographic atrophy). 
NovaLign: US
First investment: 2005 - Seed NovaLign based in Duluth, GA; is developing a minimally invasive implant for long bone fixation. Formerly know as OsteoLign. 
ReShape: US
First investment: 2005 - Seed ReShape is a seed stage project within the Intersect Partners incubator developing an endoscopically placed device for the treatment of obesity. 
Sadra Medical: US
First investment: 2003 - Seed Sadra based in Campbell, CA, is developing an innovative new approach to aortic valve disease through a minimally invasive percutaneous replacement solution. 
Socios Mayores en Salud: US
First investment: 2006 - Expansion Socios based in San Juan, Puerto Rico, is a Medicare HMO. 
Spinal Kinetics: US
First investment: 2005 - Early Stage Spinal Kinetics based in Redwood City, CA, is developing a 3rd generation artificial disc for cervical and lumbar spine surgery as an alternative to fusion. 
Sutro Biopharma, Inc.: US
First investment: 2006 - Early Stage Sutro Biopharma's mission is to enable the production of low-cost, high quality rapidly developed protein pharmaceuticals and innovative vaccines that cannot be manufactured by existing technologies. Previously known as Fundamental Applied Biology’s (FAB). 
US Renal Care: US
First investment: 2005 - Expansion US Renal Care(USRC) based in Dallas, TX, provides dialysis services to patients with end stage renal disease (ESRD) through the ownership and management of freestanding dialysis clinics. The company partners with local nephrologists in secondary markets underserved by dialysis consolidators. SV Life Sciences Fund IV (SVLSFIV)
Accelecare Wound Centers: US
First Investment: 2007 - Buyout Accelecare provides full service management, operation and medical team staffing of wound healing and hyperbaric medicine centers at hospitals throughout the South Central and Central portion of the US. 
Adimab: US
First investment: 2007 - Start Up Adimab, Inc. is developing a fully integrated platform for antibody discovery and manufacturing which will offer customers/ acquirers a 3rd party royalty free and very rapid, 2-3 month path from target to optimized antibody. 
Affinium Pharmaceuticals : US
First investment: 2007 - Early Stage Affinium Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines stemming from the bacterial fatty acid synthesis pathway. 
Allocure: US
First investment: 2008 - Early Stage Allocure is a biotechnology company at the forefront of innovative cell therapies for the treatment of acute kidney injury. 
Altura Medical: US
First investment: 2008 - Seed Altura is a seed stage company within Intersect Partners developing a low profile stent graft for the treatment of abdominal aortic aneurysms (AAA). Formerly known as Altura Interventional. Antiva: UK First investment: 2008 - Start Up Antiva, is a spin out business from Vantia www.vantiatherapeutics.com and alongside that business focuses on leading research based healthcare into improving clinical treatments through development & commercialisation of innovative medicines. 
Cardiomind: US
First Investment: 2007 - Early Stage CardioMind is a medical device company developing novel nitinol-based stents and an innovative, balloon-free stent delivery system for small, difficult-to-access vessels. 
Celerion: US
First investment: 2010 - Start Up Celerion is the privately owned CRO formed through the acquisition of the development and regulatory services consultancy and early clinical development operations of MDS Pharma Services. 
CR: US
First Investment: 2008 - Buyout CR is a holding company whose management team intends to develop a global CRO providing outsourced clinical monitoring, data management and other related services for biotechnology and pharmaceutical companies conducting Phase II-IV clinical trials. The first of CR’s transactions included Trio Clinical Research (www.trioclinicalresearch.com), an innovative clinical research services company. 
CRI Worldwide: US
First Investment: 2007 - Buyout CRI Worldwide, founded in 2000, is a CNS focused network of clinical research facilities conducting phase I-III trials (mostly inpatient studies). CRI operates research units in partnership with local area hospitals providing “flexible” bed arrangements and yet they are able to use a central IRB. 
Delenex Therapeutics: Switzerland
First investment SVLSF IV: 2009 - Early Stage Delenex is a spin out from ESBATech, an investment that was divested in 2009. The business focuses on research and development in to its antibody fragments for delivering next generation Therapeutics application. 
Entellus: US
First investment: 2006 - Early Stage Entellus is a company developing medical device therapies for nasal and sinus disease. 
EUSA Pharma : UK
First investment: 2007 - Expansion EUSA Pharma (EUSA) is a fast growing, transatlantic specialty pharma company developing and commercialising for healthcare professionals and patients a range of prescription products in pain, oncology and critical care. 
Halscion: US
First Investment: 2007 - Seed Halscion is seed-stage company founded by The Innovation Factory which is developing a biomaterial for wound management. ISG Holdings: US First investment: 2008 - Seed ISG Holdings is a business offering workers compensation scheme outsourcing by businesses with US operations. 
Itero Biopharmaceuticals: US
First investment: 2007 - Early Stage Itero is an early stage biosimilars company focused on the large number of product opportunities with product patents. 
Juvaris BioTherapeutics: US
First Investment: 2009 - Early Stage Developing novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. 
LenSx Lasers, Inc: US
First Investment: 2008 - Start Up LenSx is developing a novel computer controlled, femtosecond laser system that can integrate multiple refractive surgical procedures performed in the cornea and lens. 
Link Medicine: US
First Investment: 2008 - Early Stage Link Medicine is a clinical stage company spun out of Harvard University working on disease-modifying therapies for neurodegenerative diseases. 
Logical Therapeutics: US
First investment: 2007 - Start Up Logical Therapeutics is a clinical stage drug development company with a focus on inflammation. The lead product, LT-NS001, is a prodrug of naproxen designed to minimize GI toxicity. The company is also working on a prodrug of aspirin, also designed to minimize GI toxicity. MindFrame: US First investment: 2007 - Seed MindFrame is a seed stage company formed out of Intersect Partners developing a novel mechanical device for the treatment of ischemic stroke. 
Mpex Pharmaceuticals: US
First SVLSF IV Investment: 2009 - Early Stage Mpex based in San Diego, CA, is focused on the discovery and development of new-antibacterial drugs that meet the growing clinical need created by multi-drug resistant bacteria. Mpex has identified several approaches to increase the effectiveness of existing antibiotics and decrease the incidence of drug resistance to these antibiotics. Mpex’s first product will be an inhaled antibiotic for serious lung infections. 
NeurogesX (NGSX): US
First Investment: 2007 - PIPE NeurogesX is developing novel topical products to relieve chronic pain and improve quality of life. 
NKT Therapeutics, Inc: US
First Investment: 2007 - Early Stage NKT Therapeutics is a biotechnology company focused on developing therapeutics based on a unique subset of immune cells called natural killer T (”NKT”) cells. 
Ocular Therapeutix: US
First Investment: 2008 - Start Up I-Therapeutix is a medical device company that is currently engaged in development of in situ formed hydrogel therapeutic products specifically for ophthalmology. Formerly known as I-therapeutics . 
Ophthotech: US
First investment: 2007 - Seed Ophthotech is dedicated to developing drugs for ophthalmic diseases with high unmet medical needs. PanOptica First investment: 2009 - Seed PanOptica is a start-up company dedicated to developing drugs for ophthalmic diseases with high unmet medical needs. 
ReShape: US
First investment: 2005 - Seed ReShape is a seed stage project within the Intersect Partners incubator developing an endoscopically placed device for the treatment of obesity. 
Sadra Medical: US
First investment: 2003 - Seed Sadra based in Campbell, CA, is developing an innovative new approach to aortic valve disease through a minimally invasive percutaneous replacement solution. Spectrum Professional Services: US First investment: 2007 - Buyout Spectrum Professional Services is building a suite of services to provide to nursing homes and other long term care facilities on an outsourced basis. The initial platform acquisition is focused on the contract rehabilitation therapy area. 
TransEnterix: US
First Investment: 2007 - Early Stage TransEnterix is developing a surgical platform that provides all the benefits of a multi-port laparoscopic surgical approach while retaining a single port of entry through a natural body orifice or via the umbilicus. 
ValenTx: US
First investment: 2009 - Early Stage ValenTx, Inc., a medical device company, develops less invasive treatments for morbid obesity. 
Vantia Pharmaceuticals: UK
First investment: 2008 - Start Up Vantia Therapeutics is a leading research based healthcare company dedicated to improving clinical treatments through development & commercialisation of innovative medicines. 
Vitalize Consulting Solutions: US
First Investment: 2007 - Buyout Vitalize Consulting Solutions, Inc. provides the highest quality clinical and business solutions to healthcare organizations across the United States and Canada. Their main focus is in the areas of application implementation and enhancement, process optimization, interfaces, project management, technology and integration, training and knowledge transfer. SV Life Sciences Fund V (SVLSFV)
Bicycle Therapeutics: UK First investment 2009 – Seed Developing a platform technology that may enable the creation of a new generation of biotherapeutics. 
Broadlane: US
First investment 2009 – Development Group Purchasing Organisation (’GPO’) focused on the acute health care sector. 
Catabasis Pharmaceuticals: US
First Investment 2010 – Start up Developing therapeutics of the treatment of inflammatory and metabolic diseases. The Corner Pharmacy: US First investment 2010 - Development An owner and operator of hospital-based retail pharmacies through joint ventures with hospital systems. 
| |
